跳至主要内容
临床试验/NCT03865615
NCT03865615撤回2 期

The Effects of Intranasal Oxytocin on Approach Bias and Craving in Moderate to Heavy Alcohol Drinkers

Jennifer Mitchell1 个研究点 分布在 1 个国家开始时间: 2023年11月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
撤回
试验地点
1
主要终点
Alcohol cue craving score

研究概览

简要总结

This will be a laboratory-based investigation of the behavioral and neural effects of intranasal oxytocin on craving for alcohol and approach bias in moderate to heavy alcohol using subjects. This study uses a within-subject, randomized, placebo-controlled, counterbalanced, crossover design to compare the effects oxytocin and placebo. In this way, all subjects will be scanned twice; once following oxytocin administration and once following placebo administration, and will complete a series of behavioral tasks (both in and out of the scanner) at both visits.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
21 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy volunteers who are 21-40 years of age
  • If female, 10 or more alcoholic drinks must be consumed weekly.
  • If male, 14 or more alcoholic drinks must be consumed weekly.
  • Meets DSM-V criteria for Alcohol Use Disorder (AUD).
  • Score 8 or greater on the Alcohol Use Disorders Identification Test (AUDIT)
  • If female, must be non-lactating, not pregnant, and using a reliable contraception method (i.e. abstinence, intrauterine device [IUD], hormonal birth control, or barrier method).
  • Native English speaker
  • Right handed
  • High school graduate or equivalent.
  • Able and willing to provide an informed consent.
  • Able to understand and follow the instructions of the investigator

排除标准

  • Positive urine drug screen (except marijuana).
  • Using cocaine, stimulants (other than nicotine and caffeine), amphetamines, hallucinogens, ecstasy, opiates, sedatives, pain pills, sleeping pills, or other psychoactive drugs within 2 weeks of the start of the study (except marijuana).
  • Marijuana use more than 3 times/week.
  • Current enrollment in an alcohol, or other drug treatment program or current legal problems relating to alcohol, or other drug use.
  • Currently trying to quit alcohol use.
  • History of major alcohol related complications within the preceding 2 years (liver failure/cirrhosis, pancreatitis, esophageal varices, etc.).
  • Has a history of atrophic rhinitis, recurrent nose bleeds, cranial surgical procedures, hypophysectomy, chronic congestion, or sinus problems.
  • Has a history of cardiac arrhythmia.
  • Clinically significant medical or psychiatric illness requiring treatment as determined by screening blood tests, medical history, and/or physical exam performed or reviewed by the study physician.
  • Severely low blood (< 90/50) pressure or uncontrolled high blood pressure (>160/100).
  • SGPT/ALT or SGOT/AST values greater than 2x upper limit of normal.
  • BAC level > 0.00% at the beginning of screening visit (within margin of error of detection).
  • Has a neurological dysfunction or psychiatric disorder (confirm with study physician).
  • Has a history of brain trauma (confirm with study physician).
  • Has an allergy or intolerance to oxytocin.
  • Has received an investigational drug within 30 days of Screening Visit.
  • Has any MRI scanning contraindications.
  • Has a history of claustrophobia.

研究组 & 干预措施

Oxytocin First

Experimental

Subjects will receive oxytocin prior to their first scanning session, and placebo prior to their second scanning session.

干预措施: Oxytocin (Drug)

Oxytocin First

Experimental

Subjects will receive oxytocin prior to their first scanning session, and placebo prior to their second scanning session.

干预措施: Placebo (Drug)

Placebo First

Experimental

Subjects will receive placebo prior to their first scanning session, and oxytocin prior to their second scanning session.

干预措施: Oxytocin (Drug)

Placebo First

Experimental

Subjects will receive placebo prior to their first scanning session, and oxytocin prior to their second scanning session.

干预措施: Placebo (Drug)

结局指标

主要结局

Alcohol cue craving score

时间窗: ~ 90 minutes post study drug administration

Subjects will be asked to perform a standardized alcohol cue exposure paradigm and be asked to rate their subjective craving following alcohol cue presentation using a standard visual analog scale. Craving scores (ranging from 1-10 on VAS) will be compared across both the active study drug and placebo.

Image approach task

时间窗: ~ 90 minutes post study drug administration

Subjects will be asked to perform an image approach task where subjects are presented with a series of images and asked to pull or push a joystick following each presentation. Response direction and speed are recorded and compared across both the active study drug and placebo.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Jennifer Mitchell

Associate Professor

University of California, San Francisco

研究点 (1)

Loading locations...

相似试验